What Turning Point Therapeutics does

Turning Point Therapeutics is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in San Diego, California. The company's research and development focus is on precision oncology — designing small-molecule kinase inhibitors that target oncogenic drivers in genetically defined cancer subsets. Its most documented pipeline asset is TPX-0131, a next-generation ALK inhibitor advancing through Phase 1/2 clinical development for ALK-positive non-small cell lung cancer (NSCLC), positioned to address treatment resistance in patients who have progressed on prior ALK-directed therapy.

Turning Point's commercial scope centers on a single disclosed clinical-stage asset, with TPX-0131 progressing through dose-escalation and expansion cohorts. The product opportunity is contested — approximately 15+ biopharmaceutical competitors are pursuing ALK inhibitors for NSCLC — indicating both strong underlying clinical demand and material competitive pressure for differentiated resistance coverage. The company previously traded on NASDAQ under the ticker TPTX and is now in delisted status, signaling a change in capital structure or ownership during the observed period.

Turning Point Therapeutics raised approximately $1.18 billion in cumulative equity funding across multiple rounds between 2014 and 2020, with the bulk concentrated in 2019-2020 capital markets activity (~$1.04B across three rounds). Backers include healthcare-specialized investors such as Foresite Capital, venBio Partners, Lilly Asia Ventures, OrbiMed, Cormorant Asset Management, SR One, HBM Healthcare Investments, Kenson Ventures, Nextech Invest, and SV Tech Ventures. As a clinical-stage developer with no approved products, revenue is not commercial in nature; the company funds operations through equity capital with 251-500 employees supporting discovery, clinical development, and regulatory functions under a leadership team that includes Founder/Director Jingrong Cui, EVP/CMO Mohammad Hirmand, and EVP/CSO Siegfried Reich.

Name

Turning Point Therapeutics

Legal name

Bristol-Myers Squibb Company

Website

https://tptherapeutics.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

251–500 employees

Short description

Turning Point Therapeutics is a clinical-stage biopharmaceutical company founded in 2013 in San Diego, developing precision kinase inhibitor therapies targeting oncogenic drivers in cancer, with lead candidate TPX-0131 in Phase 1/2 for ALK-positive NSCLC.

Ownership category

akta.pro rank

Product category

Precision Oncology Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

Translational Medicine & Biomarkers (HLAIALAF), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD)

Keywords

• Precision oncology
• Kinase inhibitors
• Targeted cancer therapy
• Biopharmaceutical drugs
• Oncology therapeutics

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Core offering

Turning Point Therapeutics is a clinical-stage biopharmaceutical company that designs and develops precision oncology medicines, with a primary focus on next-generation kinase inhibitors targeting genetic drivers of cancer. Its lead asset, TPX-0131, is a novel ALK inhibitor designed to address resistance mutations in patients with ALK-positive non-small cell lung cancer (NSCLC), currently being evaluated in Phase 1/2 clinical trials.

Product overview

Turning Point Therapeutics is a biopharmaceutical company developing targeted oncology therapies. The company's primary pipeline asset mentioned in available sources is TPX-0131, an ALK inhibitor in Phase 1/2 clinical trials for ALK-positive non-small cell lung cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• TPX-0131

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Pfizer: Pfizer markets Lorbrena (lorlatinib), a third-generation ALK inhibitor approved for ALK-positive NSCLC. It is the most directly comparable marketed competitor to Turning Point's TPX-0131 in the same molecular target and indication.
• BeiGene: BeiGene is a global oncology company with a broad targeted-therapy pipeline including kinase inhibitors for NSCLC. Overlaps with Turning Point in precision-oncology drug development and competing in similar indications.
• Genentech (Roche): Genentech/Roche markets Alecensa (alectinib), a leading ALK inhibitor for ALK-positive NSCLC. Operates in the same biomarker-defined patient population targeted by Turning Point Therapeutics.
• Mirati Therapeutics: Mirati Therapeutics is a precision oncology company focused on targeted therapies for cancer, including KRAS and other oncogenic drivers. Comparable business model and clinical-stage precision-oncology approach to Turning Point Therapeutics.
• Novartis: Novartis markets Zykadia (ceritinib), an ALK inhibitor for ALK-positive NSCLC, and has a broader precision-oncology portfolio. Directly overlaps with Turning Point on the ALK target and serves as a benchmark large-cap competitor.
• Blueprint Medicines: Blueprint Medicines is a precision oncology company developing kinase inhibitors for genomically defined cancers. Operates with a similar biomarker-driven discovery-to-clinical approach as Turning Point Therapeutics.
• Takeda Pharmaceutical: Takeda markets Alunbrig (brigatinib), an ALK inhibitor approved for ALK-positive NSCLC. Directly competes with Turning Point in the same target and indication.

Emerging players

• Nuvalent: Nuvalent is a clinical-stage precision oncology company developing NVL-655, a next-generation ALK inhibitor designed to address resistance mutations. Closely mirrors Turning Point's strategy with TPX-0131 in targeting resistance-driven ALK-positive NSCLC.

Broad incumbents

• AstraZeneca: AstraZeneca has a major oncology franchise (Tagrisso, Enhertu, Imfinzi) and is active in NSCLC. Represents a large-cap strategic acquirer and broad incumbent competing in the same disease area as Turning Point's lead asset.
• Bristol Myers Squibb: Bristol Myers Squibb is a large-cap biopharma with a broad oncology franchise across solid tumors and hematology. Provided source explicitly references M&A activity as a key strategy, and BMS is the acquirer most associated with Turning Point's delisting and corporate outcome.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/TPTherapeutics
• YouTubeyoutube.com/bristolmyerssquibb
• Facebookfacebook.com/BristolMyersSquibb
• LinkedInlinkedin.com/company/6727624
• Instagraminstagram.com/bristolmyerssquibb

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds8 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Turning Point Therapeutics